Cardiovascular Medicine and Haematology articles for United Kingdom (UK)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 335

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.01
Toward a ToxAtlas of Carbon-Based Nanomaterials: Single-Cell RNA Sequencing Reveals Initiating Cell Circuits in Pulmonary Inflammation 0.01
1 0.85
Micromechanical heterogeneity in abdominal aortic aneurysms is associated with rupture risk 0.85
1 0.93
A Bespoke Programmable Interpenetrating Elastomer Network Composite Laryngeal Stent for Expedited Paediatric Laryngotracheal Reconstruction 0.93
1 0.47
Prognostic value of adiposity indices in anticoagulated patients with atrial fibrillation: The prospective Murcia AF Project III cohort 0.47
1 0.38
Reproductive factors and the risk of incident peripheral arterial disease hospitalisation or death: A cohort study of UK Biobank participants 0.38
25 8.93
Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials 0.29
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use 0.08
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial 0.04
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.06
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial 0.04
Mast Cells and Endothelial Cells Mediate Interleukin-33 and ST2 Responses in Distal COPD Lungs 0.29
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations 0.07
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.18
Lower airway immunophenotyping in severe preschool wheeze reveals distinct clusters described by heterogeneity in neutrophil phenotypes 1.00
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial. 0.13
Phenotyping Asthma and/or COPD Using 129Xe MRI and Comprehensive Physiologic Testing. 0.93
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.60
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.19
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage COPD. 0.05
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.73
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.10
Non-Coding DNA Variants Increase the Genetic Diagnostic Yield in Primary Ciliary Dyskinesia. 1.00
Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome 0.73
Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4). 1.00
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.01
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.10
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.06
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study 0.88
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.05
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE) 0.33
1 0.87
Evaluation of Out-of-Hospital Use of a Valsalva Assist Device in the Emergency Treatment of Supraventricular Tachycardia 0.87
2 0.22
Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study : A Randomized Controlled Trial. 0.18
Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk : A Target Trial Emulation Study. 0.04
2 1.13
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Have Distinct Prediagnostic Blood Biochemical Profiles 1.00
Carotid Revascularization Versus Medical Management for Ischemic Stroke with Ipsilateral Carotid Web: A Systematic Review and Meta‐Analysis 0.13
2 0.31
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease 0.06
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.25
7 2.43
Lung ultrasound for the detection of radiological progression of interstitial lung abnormalities in patients with rheumatoid arthritis 0.13
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.06
Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study 0.62
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis 0.27
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis 0.25
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations 0.10
B cells and systemic sclerosis interstitial lung disease 1.00
6 1.62
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma 0.30
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 0.03
Delineating iMpl/i-dependent and -independent phenotypes of iJak2/i V617F–positive MPNs in vivo 0.41
A novel cause of type 1 Von Willebrand Disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants 0.17
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma 0.54
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.18
2 0.10
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.07
Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle 0.03
3 3.00
Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis 1.00
Open thoracoabdominal aortic aneurysm repair: results from a national service 1.00
Long-term mortality rate and clinical outcomes associated with femoro-popliteal drug–coated balloon angioplasty and drug-eluting stents in chronic limb-threatening ischaemia: an analysis of the BASIL-3 RCT 1.00
1 0.06
Dual-site recognition leads to a ratiometric fluorescent probe for norepinephrine: quantitative detection and visualization for in-depth understanding of hypertension 0.06
13 5.86
The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis 0.36
Clinical Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation for People in Uganda With Post-TB Lung Disease 0.60
Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study 0.04
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers 0.33
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.14
Aspergillus fumigatus sensitization is associated with high-risk bronchiectasis 0.20
Initial Evaluation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR) Measurement Properties: A Patient-Focused Measure 0.30
Lung Cancer Risk in Preserved Ratio Impaired Spirometry and Airway Obstruction: A UK Biobank Study 0.17
An inventory of clinical sarcoidosis status in the United States 0.14
Inflammatory and mucociliary dysfunction based endotypes across the spectrum of chronic airway diseases 0.96
Mortality Outcomes and ACE Inhibitor Use in Patients with Idiopathic Pulmonary Fibrosis 0.70
Clustering Patients With Chronic Cough Using Reported Sensations and Triggers: Results from the Triggers and Sensations Provoking Coughing Questionnaire 0.92
Incidence of discordant pleural fluid exudates and diagnostic patterns – a retrospective cohort study 1.00
19 4.16
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients 0.07
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study. 0.97
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.17
Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. 0.04
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.05
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.03
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes. 0.63
Bradycardia in Athletes: Prevalence, Mechanisms, and Risks. 0.02
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. 0.08
Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. 0.70
The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. 0.97
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.07
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. 0.08
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.04
Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. 0.04
Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. 0.09
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.08
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.01
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study. 0.06
1 1.00
Cardiovascular Subphenotypes in Sepsis 1.00
3 2.40
Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study 1.00
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL. 0.40
Glucose Control, Sulfonylureas, and Insulin Treatment in Older Adults With Type 2 Diabetes and Risk of Falls and Fractures: An Observational Study. 1.00
2 0.92
A longitudinal cohort study of damp and mouldy housing and children's respiratory health in Bradford, UK 0.75
TRPA1 mediates ozone-induced murine model of COPD through the Wnt5a/GSK-3β/β-catenin pathway 0.17
1 0.10
Lifetime urban exposure, socioeconomic position and respiratory health among adolescents 0.10
39 11.12
Right aortic arch and double arch assessed by prenatal echocardiography: a population-based study 1.00
Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrate 0.44
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials 0.11
A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trial 0.03
Cancer and heart failure: prevalence, incidence, and prognosis in Scotland 0.75
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort 0.04
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.09
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.26
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.36
Laminopathies: natural history and risk prediction of heart failure 0.03
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study 0.09
Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study 0.02
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial 0.07
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.14
Spatial transcriptomics reveals a key role of fibroblast-like vascular smooth muscle cells in human atherosclerotic cell crosstalk and stability 0.24
Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease 0.08
The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk 0.13
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.06
Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial 0.06
Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction 0.82
Diabetes and sudden cardiac death: a Danish nationwide study 0.13
Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study 0.55
Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study 0.18
High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study 0.88
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.07
Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study 0.81
Left ventricular geometry, brain architecture, and cognition: an observational study 0.90
Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study 0.04
Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial 0.04
Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging 0.03
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial 0.06
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.08
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction 0.18
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.11
First myocardial infarction: risk factors, symptoms, and medical therapy 0.07
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
Mode of revascularization for ischaemic cardiomyopathy: comparing apples with oranges? 1.00
Clinical implications of sex-related differences in severe aortic stenosis 1.00
Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis 0.15
3 2.11
A cohort study of forced vital capacity, airway obstruction, and survival in the multinational Burden of Obstructive Lung Disease study 0.24
Comorbidity of asthma and attention deficit hyperactivity disorder in childhood: causal, shared early-life risk factors, or shared genetic liability? 0.88
Human genetics suggests differing causal pathways from HMGCR inhibition to coronary artery disease and type 2 diabetes 1.00
2 1.25
Circulating lipid subfractions and the risk of longitudinal adiposity progression: findings from the China Kadoorie Biobank 0.25
Modelling the direct and indirect associations between anthropometric and behavioural factors when predicting atherogenic risk index (TC/HDL-C) ratio 1.00
1 0.30
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes 0.30
9 2.02
Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. 0.04
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.27
Digoxin in Patients With Symptomatic Rheumatic Heart Disease 0.01
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease 0.02
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.31
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.31
Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia 0.05
Remote Screening for Asymptomatic Atrial Fibrillation 1.00
3 1.91
Phosphorylation of inner core heptose is a major determinant of bacterial surface lipopolysaccharide recognition by the innate immune protein hSP-D 0.88
TET2 has endothelial-specific roles in interferon responses that are dysregulated by hyperglycaemia in vitro and in vivo 1.00
A dual role of fibroblast–epithelial crosstalk in acute and chronic lung injury 0.04
2 0.84
Loss of RPGR disrupts motile cilia and causes primary ciliary dyskinesia by affecting F-actin dynamics 0.06
Platelet-specific SLFN14 deletion causes macrothrombocytopenia and platelet dysfunction through dysregulated megakaryocyte and platelet gene expression 0.78
5 1.22
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. 0.92
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.02
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. 0.10
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.07
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.11
1 0.01
Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort 0.01
6 4.68
Multiscale mechanistic modelling of heterogeneity in cardiac sub‐cellular calcium handling accounting for variable t‐system density 0.67
Sarcolemmal and mitochondrial membrane potentials measured ex vivo and in vivo in the heart by pharmacokinetic modelling of [99mTc]sestamibi 1.00
An age‐associated decline in the role of the sarcoplasmic reticulum and associated calcium‐handling proteins sets the pace for sinoatrial node function 1.00
Human‐derived cardiac‐neural microtissues reveal catecholaminergic polymorphic ventricular tachycardia is also a disease of the sympathetic neuron 0.65
Anti‐arrhythmic targeting of sympathetic stellate ganglion P2X3 receptors 0.36
Dietary flavanols preserve upper‐ and lower‐limb endothelial function during sitting in high‐ and low‐fit young healthy males 1.00
6 1.99
Safety and Efficacy of a Dedicated Pulmonary Thromboendarterectomy Fellowship: the UK Experience at a High-Volume Center 0.60
Multi-Center Comparison of Hybrid and Norwood Procedure in Patients with Fontan Circulation 0.12
Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair 0.14
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.06
Personalized External Aortic Root Support, the Dutch Experience 0.07
A cohort evaluation of surgical pathways reported to a national audit of children undergoing treatment for congenital heart disease in England and Wales 1.00
1 0.25
Biorthogonal PEGylation of Hierarchical Porous Metal–Organic Frameworks as Robust, Functional Nanocarriers for Hemoglobin-Based Oxygen Delivery 0.25
36 7.70
Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease 0.09
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study 0.29
Focal and Diffuse Coronary Artery Disease Patterns and Placebo-Controlled Angina Relief With Percutaneous Coronary Intervention 1.00
Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus 0.10
Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis 0.06
Cardiovascular Disease Risk in Adults With Hematological Malignancies 0.11
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial 0.17
A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO 0.90
Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation 0.10
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure 0.17
Comparative Prognosis of Chagas and Other Cardiomyopathies 0.33
Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals 0.96
Association Between Age and PCI Effectiveness in Stable CAD Secondary Analysis of ORBITA-2 0.92
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension A Randomized Phase 2 Trial 0.10
Blood Pressure Levels and Outcomes in Type 2 Diabetes Dose-Response Meta-Analysis of 5.87 Million Cohort Participants 0.02
Heart Failure Quality of Care Among Asian Patients in the United States 0.08
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial 0.03
Potent P2Y12 Inhibitor Monotherapy versus DAPT after PCI in Patients With and Without STEMI: NEO-MINDSET Substudy 0.03
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial 0.05
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.13
Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial 0.04
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction 0.05
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials 0.13
Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department A Secondary Analysis 1.00
Drug-coated balloon angioplasty versus upfront stenting for de novo CAD: 3-year follow-up of REC-CAGEFREE I trial 0.06
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.07
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes An Emulation 0.05
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.03
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis 0.10
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial 0.05
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM 0.03
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial 0.04
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.13
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.13
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study 0.04
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.14
1 0.29
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.29
1 0.01
Imidazole propionate is a driver and therapeutic target in atherosclerosis 0.01
26 9.61
Gene-gene interactions between a LMNA variant and common polymorphisms drive early-onset atrial fibrillation 0.30
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis 0.06
Endothelial-erythrocyte glycocalyx exchange enables liquid biopsies of endothelial function 0.95
International trade and air-quality-related mortality 0.25
Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis 0.02
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.12
TWIST1 drives endothelial-to-mesenchymal-transition to stabilize atherosclerotic plaques 0.53
The landscape of hereditary haemochromatosis risk and diagnosis across the British Isles and Ireland 0.50
Endothelial stem cells of the retinal vasculature reside in the optic nerve 0.07
Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment 0.75
Nano-functionalized probiotic treats atherosclerosis via inhibiting intestinal microbiota-TMA-TMAO axis 0.09
Identification of epigenetic regulators of fibrotic transformation in cardiac fibroblasts through bulk and single-cell CRISPR screens 0.31
A cross-study transcriptional patient map of heart failure defines conserved multicellular coordination in cardiac remodeling 0.26
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.25
Predicting hypotension, syncope, and fracture risk in patients indicated for antihypertensive treatment: the STRATIFY models 0.97
mTOR dysregulation induces IL-6 and paracrine AT2 cell senescence impeding lung repair in lymphangioleiomyomatosis 0.62
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma 0.03
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.03
Lung structural cells are altered by infeluenza virus leading to rapid immune protection following re-challenge 0.95
Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure 0.03
Scavenger receptor CD163 multimerises to allow uptake of diverse ligands 1.00
Colchicine in patients with aortic stenosis undergoing transcatheter aortic valve replacement: a double-blind randomized trial 0.03
Cross-population GWAS and proteomics improve risk prediction and reveal mechanisms in atrial fibrillation 0.12
Connective tissue disorder and high risk pregnancy: a case series with personalised external aortic root support (PEARS) 1.00
PI3Kγ signaling controls trafficking of CD8+ T cells between lymphoid and non-lymphoid organs and drives hypertension in a murine model 0.10
Imbalanced TGFβ signalling and autophagy drive erythroid priming of hematopoietic stem cells in β-thalassemia 0.29
13 3.23
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.14
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.18
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial 0.17
Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas 0.22
Long-term risk of death after tuberculosis diagnosis and treatment 0.31
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.09
Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial 0.01
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.10
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial 0.96
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.03
Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial 0.93
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.04
Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial 0.06
3 1.56
Impact of abdominal obesity prevalence trends on dementia, cardiovascular disease, functional impairment, and mortality in older Chinese adults: A Markov scenario simulation, 2020–2050 0.42
Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study 0.14
NT-proBNP testing for heart failure diagnosis in people with atrial fibrillation: A diagnostic accuracy study 1.00
5 2.98
Spatial control of myosin regulatory light chain phosphorylation modulates cardiac thick filament mechanosensing 0.10
<atl>Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis–causing iCFTR/i variant</atl> 0.83
Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis 0.04
Nitric oxide promotes cysteine N-degron proteolysis through control of oxygen availability 1.00
Cilia dynamics create a dynamic barrier to penetration of the periciliary layer in human airway epithelia 1.00
1 0.07
Right Ventricular Strain Improves Cardiac MRI-based Prognostication in Heart Failure with Preserved Ejection Fraction. 0.07
1 0.05
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.05
3 0.82
The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis 0.09
Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation 0.60
NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors 0.13
3 1.61
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension 0.65
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma 0.03
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy 0.92
4 1.07
Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS)) 0.84
Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China 0.04
Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis 0.11
P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials 0.08
1 1.00
Prothrombinase processivity is conferred by substrate allostery 1.00
5 1.73
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.03
Differential effects of subcutaneous and sublingual immunotherapy on timothy grass–specific TH2 CD4+ T-cell subsets 0.17
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.32
Genetic characterization of preschool wheeze phenotypes 0.22
Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma 1.00
16 2.48
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial 0.04
Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial 0.35
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study 0.41
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.03
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.03
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials 0.11
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial 0.66
Budesonide–formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial 0.06
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial 0.05
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.03
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials 0.02
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials 0.18
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial 0.04
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) 0.37
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.04
1 0.53
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis 0.53
1 0.17
Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis 0.17
21 3.17
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia 0.32
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage 0.07
Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease 0.02
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease 0.06
Angiography-Based Physiology to Guide Coronary Revascularization 0.12
Angiography-Derived Fractional Flow Reserve to Guide PCI 0.04
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 0.06
Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation 0.01
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction 0.02
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation 0.02
A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia 0.03
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction 0.11
Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 0.02
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.05
Hypertonic Saline or Carbocisteine in Bronchiectasis 1.00
Home-Based Care for Hypertension in Rural South Africa 0.12
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes 0.03
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction 0.01
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 0.04
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy 0.03
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia 1.00
20 13.06
Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study 0.39
At-risk registers integrated into primary care to stop asthma crises in the UK: cluster randomised controlled trial with economic evaluation 0.96
Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort 0.06
Clinical and cost-effectiveness of SPACE for COPD delivered as a pulmonary rehabilitation maintenance programme: a randomised controlled trial 0.92
Comparison of Lower Airway Sampling Strategies in Children with Protracted Bacterial Bronchitis (CLASSIC-PBB): a non-randomised, internally controlled, multicentre trial 1.00
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study 0.55
Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study 0.95
Impact of air pollution on lung function in cystic fibrosis over a decade in London: a UK CF Registry study 1.00
Clinical impact of customised positive airway pressure (PAP) therapy interfaces (3DPiPPIn): a single site randomised controlled trial 1.00
Elastic parametric response mapping: quantitative CT scoring for local COPD severity 0.13
Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD 0.29
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial 0.69
Understanding the bidirectional relationship between chronic respiratory disease and cardiovascular disease using genetic evidence 1.00
Time to diagnosis and long-term outcomes for adults presenting with breathlessness 1.00
Safety, feasibility and efficacy of exercise as an airway clearance technique in cystic fibrosis: a randomised pilot feasibility trial 1.00
Acute breathlessness as a cause of hospitalisation in Malawi: a prospective, patient-centred study to evaluate causes and outcomes 0.32
Effect of simvastatin on postoperative complications in patients undergoing one-lung ventilation during surgery: the Prevention HARP-2 randomised controlled trial 1.00
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts 0.44
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.27
Associations of interstitial lung disease subtype and CT pattern with lung function and survival 0.08

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.